▲    Song Jin-young, External Relations Team Leader of the Center, presenting the Track Record

On April 29 (Tuesday), a seminar and networking event with industry experts was held at Seoul Bio Hub PCMO (Director Cho Min, hereinafter referred to as "the Center") announced the successful conclusion of the "Innovation Convergence Summit – New Drug Materials and Nonclinical Demonstration" held at Seoul Bio Hub.

This event was co-hosted with Chonnam National University Hwasun Hospital and aimed to support the commercialization of innovative new drug materials. Targeting companies in the pharmaceutical and biotechnology sectors, the event featured experts across the full spectrum of new drug development, including CDMO (Contract Development and Manufacturing Organization), CRO (Contract Research Organization), and GMP consulting, offering an opportunity to review development processes and expand networks.

In the first part of the seminar, the Center presented its plans to expand public CDMO operations based on the upcoming mRNA manufacturing facility scheduled to be operational in Q3 2025. It also shared its six-year track record and highlighted the unique strengths and differentiation of public CDMOs. Other engaging presentations included Chonnam National University Hwasun Hospital’s corporate support cases and program introduction, GMP international trends by Jung Jae-ho, Executive Vice President of BNP Care, and R&D development strategies for value enhancement by Kim Hee-sun, CEO of BXPlant.

▲    Networking session at the Innovation Convergence Summit

The second part of the event featured a networking session with CDMOs, research institutions, and materials/components/equipment (MCE) companies from the Seoul metropolitan area. Discussions on potential joint business developments took place, and practical information exchange opportunities were provided through interactions with resident companies at Seoul Bio Hub.

A Center representative stated, “As private investment, including venture capital (VC) and angel funding, has declined in the current pharmaceutical and biotechnology market, many new drug development pipelines are being halted,” adding, “Until the investment environment recovers, the Center is prepared to provide substantial support in various aspects, and we welcome active inquiries.”